{"id":608164,"date":"2024-06-07T14:52:34","date_gmt":"2024-06-07T18:52:34","guid":{"rendered":"https:\/\/platohealth.ai\/glp-1-treatment-displays-best-in-class-potential-for-mash\/"},"modified":"2024-06-07T15:41:09","modified_gmt":"2024-06-07T19:41:09","slug":"glp-1-treatment-displays-best-in-class-potential-for-mash","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/glp-1-treatment-displays-best-in-class-potential-for-mash\/","title":{"rendered":"GLP-1 treatment displays best-in-class potential for MASH","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
\n

These results from the Phase II trial could lead to clinically meaningful benefits for cardiovascular, renal, and metabolic diseases, Boehringer Ingelheim suggests.<\/p>\n<\/div>\n

\n\"survodutide\"survodutide<\/div>\n

New sub-analysis data from a Phase II clinical trial<\/a> show that after 48 weeks of survodutide treatment, 83.0 percent of adults with liver fibrosis achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH). This is compared to 18.2 percent with placebo.<\/p>\n

With its novel mechanism of action, the glucagon\/GLP-1 receptor dual agonist<\/a> is the first to show this level of fibrosis benefit in a Phase II MASH trial following 48 weeks of treatment, according to Boehringer Ingelheim.<\/p>\n

Potential of survodutide<\/h2>\n

Results presented at European Association for the Study of the Liver Congress (EASL) 2024 revealed that after 48 weeks of treatment:<\/strong><\/p>\n

Actual treatment results revealed up to 87.0 percent of adults achieved at least a 30 percent relative reduction in liver fat. This was compared to 19.7 percent for those given placebo. A relative reduction in liver fat content of up to 64.3 percent was seen in patients treated with survodutide, versus 7.3 percent with placebo.<\/p>\n

Moreover, up to 64.5 percent of adults with moderate to advanced fibrosis were able to gain improvement in scarring without worsening of MASH, versus 25.9 percent with placebo.<\/p>\n

Secondary endpoint results demonstrated up to 52.3 percent of patients with stages F1, F2 and F3 achieved a significant improvement in fibrosis. This is compared to 25.8 percent with placebo.<\/p>\n

\n

Boehringer reveals major data from liver disease trial<\/a><\/p>\n<\/blockquote>\n

\n

\u201cbreakthrough [findings] further reinforce survodutide\u2019s potential as a best-in-class treatment for people living with MASH. We will advance quickly into Phase III trials\u201d<\/p>\n<\/div>\n

According to the Head of Human Pharma at Boehringer Ingelheim, Carinne Brouillon<\/a>, these \u201cbreakthrough [findings] further reinforce survodutide\u2019s potential as a best-in-class treatment for people living with MASH. We will advance quickly into Phase III trials\u201d.<\/p>\n

These results \u201cdemonstrate the potential for glucagon agonism, in addition to GLP-1, to both improve MASH and shift the needle on fibrosis,\u201d shared Dr Arun Sanyal<\/a>, Professor of Medicine, Physiology and Molecular Pathology at Virginia Commonwealth University School of Medicine, and Principal Investigator of the trial. \u201cThese data position survodutide as a leading glucagon\/GLP-1 receptor dual agonist that could be a game-changer for people living with MASH and clinically significant fibrosis.\u201d <\/p>\n

The full trial results were also published in The New England Journal of Medicine<\/a><\/em>.<\/p>\n

Boehringer Ingelheim noted that having licensed survodutide from Zealand Pharma, it is solely responsible for developing and commercialising the treatment worldwide.<\/p>\n